KNSA - Kiniksa's Heart Drug And Other News: The Good Bad And Ugly Of Biopharma
Kiniksa Reports Positive Phase 3 Data for Heart Inflammation Drug
Kiniksa Pharmaceuticals Ltd. (KNSA) announced positive data from its pivotal Phase 3 trial of rilonacept. The drug candidate has been given Breakthrough Therapy designation by the FDA for treating recurrent pericarditis in 2019. Kiniksa is looking to submit a Supplemental Biologics License Application for the drug later this year.
RHAPSODY trial met its predecided primary endpoints as well as major secondary efficacy endpoints. The drug candidate showed clinically meaningful results. Sanj K. Patel, CEO of Kiniksa said,
“We are pleased to announce that